

REMARKS/ARGUMENTS

This Amendment addresses issues raised in the Final Rejection of July 17, 2006 and the Advisory Action of January 17, 2007.

New claims 21-27 have been added. New claims 21 and 22 are directed to compounds *per se* and, as compared to previously examined claim 1, define a spacer to be distinct from that disclosed in the Matsumoto et al article. New claim 23 is directed to a process for preparing the novel compounds, claims 24 and 25 are directed to pharmaceutical compositions containing them and claim 26 is directed to a method of treating lung cancer by administering these compounds to a person in need of same.

New claim 27 is directed to treating a lung cancer using compounds as defined in previous claim 1.


In the Final Rejection the examiner has indicated that claims directed to the treatment of a lung cancer are enabled by the description of the invention and new claims 26 and 27 reflect this indication of allowable subject matter.

Further examination is requested. Should the examiner have any questions or require further information, please contact the undersigned.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Arthur R. Crawford
Reg. No. 25,327

ARC:eaw
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100